Tag - ADXN

An independent interim review committee (IRC), following review of unblinded data from Part 1 of patient Cohort 1, recommended Addex Therapeutics (SIX, NASDAQ:ADXN) continue with the ADX71149 Phase 2 epilepsy clinical...